LLY
Eli Lilly and Company
October 8, 2026 · intraday
- Rarity
- 1.24
- Peak move
- −4.62%
- Float cap
- $1.01T
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets human medicines sold in roughly 90 countries. Its products span cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog, Trulicity), oncology (Verzenio, Cyramza, Jaypirca), immunology (Taltz, Olumiant), and neuroscience (Emgality, Kisunla). Customers include wholesale distributors, hospitals, pharmacies, and government and commercial insurers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the movedeal_terminatedPeptron said its SmartDepot platform technology evaluation with Eli Lilly concluded on October 7 without a follow-up commercialization agreement, and Peptron shares fell about 28-30%.
institutional_flowTRex Bio plans to raise $133.3 million in an October 8 IPO on Nasdaq, with Eli Lilly & Co. as an investor ready to buy a 19.9% stake.
regulatory_approvalThe FDA expanded approval of Eli Lilly's Jaypirca (pirtobrutinib) to adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion.
clinical_readoutEli Lilly reported results from its largest and longest study of oral orforglipron (Foundayo) in adults with type 2 diabetes, showing cardiovascular safety alongside sustained reductions in blood sugar and body weight.
analyst_ratingMorgan Stanley raised its price target on Eli Lilly to $1,430 from $1,419 while maintaining a Buy/Overweight rating, citing expected strong sales of the company's weight-loss drugs.
major_contractEli Lilly expanded its collaboration and license agreement with Gate Bioscience, adding one target with an option on a second, with total potential value exceeding $870 million contingent on milestones.